Abbott announces first global procedures in a clinical trial of its volt™ pulsed field ablation system to treat patients with abnormal heart rhythms

Abbott's volt™ pulsed field ablation system is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation pulsed field ablation – or pfa – uses high energy electrical pulses for ablation procedures that may offer benefits to target and treat tissue in the heart abbott's volt pfa system is designed to overcome limitations of first-generation pfa systems by providing physicians a clearer indication of contact between the volt pfa catheter and targeted tissue abbott park, ill., jan. 18, 2024 /prnewswire/ -- abbott (nyse: abt) today announced the first global procedures have been conducted using the company's new volt™ pulsed field ablation (pfa) system to treat patients battling common abnormal heart rhythms such as atrial fibrillation (afib).
ABT Ratings Summary
ABT Quant Ranking